RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED AND REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED AND REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New universal CAR-T therapy targets tough multiple myeloma cases
Disease control TerminatedThis early-stage study tests a new type of CAR-T cell therapy, called UWD-00B, for people with multiple myeloma that has come back or not responded to other treatments. The therapy uses donor cells that are modified to target and kill cancer cells, and does not require the patien…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New drug shows promise for Hard-to-Treat blood cancer
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug elranatamab in people with multiple myeloma that has come back or not responded to other treatments. The main focus is on tracking side effects like cytokine release syndrome and nerve-related issues. Only one…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 18, 2026 11:53 UTC
-
New cell therapy trial offers hope for Hard-to-Treat myeloma
Disease control OngoingThis early-phase study tests experimental cell therapies in 40 adults with relapsed and refractory multiple myeloma who have tried at least three prior treatments. The main goal is to check safety and find the right dose. While not a cure, it aims to control the disease and may l…
Matched conditions: RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC